{"id":125769,"date":"2024-06-05T13:45:00","date_gmt":"2024-06-05T08:15:00","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=125769"},"modified":"2024-06-05T14:21:10","modified_gmt":"2024-06-05T08:51:10","slug":"pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/","title":{"rendered":"Pharma stock jumps 8% after company filed its first drug to treat blood volume loss with USFDA\u00a0"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1148915892\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>Pharma stock engaged in the business of manufacturing, sale, and research and development of generic pharmaceutical products, APIs\u2019 and many others jumped 8 percent in the day\u2019s trade upon filing its first Drug Master File of recombinant Human Albumin 20 percent with the USFDA.&nbsp;<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-798384917\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>With a market capitalization of Rs. 4,683.21 Crores, the shares of Shilpa Medicare Limited were trading at Rs. 478.90 per equity share, up 8.20 percent from its previous day\u2019s close price of Rs. 442.60.&nbsp;<\/p><p>Shilpa Medicare Limited\u2019s wholly owned subsidiary Shilpa Biologicals Pvt Ltd has filed its first Drug Master File of recombinant Human Albumin 20 percent with the USFDA. The Recombinant Human Albumin 20 percent targets to fulfill the growing demand for human serum albumin to deliver current and growing market demand. It is said to be used to treat the blood volume loss.&nbsp;<\/p><p>This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20 percent process which is completely Environment friendly, Consistent High-Quality product, Scalable to massive scales, and is cost competitive.&nbsp;<\/p><div class=\"trade-content_5\" id=\"trade-3478545967\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>Shilpa Medicare Limited is engaged in the business of manufacturing, sale, and research and development of generic pharmaceutical products, active pharmaceutical ingredients (APIs), and formulations for both domestic and international markets.&nbsp;<\/p><p>As of Q4FY24, Shilpa Medicare Limited generated 62 percent of its revenue from API, 33 percent from Formulations, 4 percent from Biologicals, and 1 percent from Others.&nbsp;<\/p><p>Its revenue from operations grew by 10.67 percent from Rs. 263.56 Crores in Q4FY23 to Rs. 291.69 Crores in Q4FY24, accompanied by a loss of Rs. 8.06 Crores to a profit of Rs. 24.5 Crores.&nbsp;<\/p><p>In terms of Return Ratios, it has reported a return on equity (ROE) of 1.72 percent, a return on capital employed (ROCE) of 5.27 percent, and a debt-to-equity ratio of 0.52.&nbsp;<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by: Bharath K.S\u00a0<\/strong><\/p><\/blockquote><h4 class=\"wp-block-heading\" id=\"h-disclaimer\"><strong>Disclaimer<\/strong><\/h4><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on <a href=\"http:\/\/tradebrains.in\/\">tradebrains.in<\/a> are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.<\/strong><\/p><div class=\"trade-after-content\" id=\"trade-1178750159\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>Pharma stock engaged in the business of manufacturing, sale, and research and development of generic pharmaceutical products, APIs\u2019 and many others jumped 8 percent in the day\u2019s trade upon filing its first Drug Master File of recombinant Human Albumin 20 percent with the USFDA.&nbsp; With a market capitalization of Rs. 4,683.21 Crores, the shares of [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":125304,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[4865,31,13525],"tags":[19035,13978,13155,948,936,3157],"class_list":["post-125769","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-analysis","category-news","category-stock-updates","tag-shilpa-medicare","tag-shilpa-medicare-acquisition","tag-shilpa-medicare-share-price","tag-stock-market","tag-stock-market-news","tag-stock-to-watch"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock jumps 8% after company filed its first drug to treat blood volume loss with USFDA\u00a0 - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"Pharma stock engaged in the business of manufacturing, sale, and research and development of generic pharmaceutical products, APIs\u2019 and many others jumped 8 percent in the day\u2019s trade upon filing its first Drug Master File of recombinant Human Albumin 20 percent with the USFDA.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock jumps 8% after company filed its first drug to treat blood volume loss with USFDA\u00a0\" \/>\n<meta property=\"og:description\" content=\"Pharma stock engaged in the business of manufacturing, sale, and research and development of generic pharmaceutical products, APIs\u2019 and many others jumped 8 percent in the day\u2019s trade upon filing its first Drug Master File of recombinant Human Albumin 20 percent with the USFDA.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-05T08:15:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-05T08:51:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/\",\"name\":\"Pharma stock jumps 8% after company filed its first drug to treat blood volume loss with USFDA\u00a0 - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\",\"datePublished\":\"2024-06-05T08:15:00+00:00\",\"dateModified\":\"2024-06-05T08:51:10+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"Pharma stock engaged in the business of manufacturing, sale, and research and development of generic pharmaceutical products, APIs\u2019 and many others jumped 8 percent in the day\u2019s trade upon filing its first Drug Master File of recombinant Human Albumin 20 percent with the USFDA.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock jumps 8% after company filed its first drug to treat blood volume loss with USFDA\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock jumps 8% after company filed its first drug to treat blood volume loss with USFDA\u00a0 - Trade Brains Features","description":"Pharma stock engaged in the business of manufacturing, sale, and research and development of generic pharmaceutical products, APIs\u2019 and many others jumped 8 percent in the day\u2019s trade upon filing its first Drug Master File of recombinant Human Albumin 20 percent with the USFDA.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock jumps 8% after company filed its first drug to treat blood volume loss with USFDA\u00a0","og_description":"Pharma stock engaged in the business of manufacturing, sale, and research and development of generic pharmaceutical products, APIs\u2019 and many others jumped 8 percent in the day\u2019s trade upon filing its first Drug Master File of recombinant Human Albumin 20 percent with the USFDA.\u00a0","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2024-06-05T08:15:00+00:00","article_modified_time":"2024-06-05T08:51:10+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/","name":"Pharma stock jumps 8% after company filed its first drug to treat blood volume loss with USFDA\u00a0 - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","datePublished":"2024-06-05T08:15:00+00:00","dateModified":"2024-06-05T08:51:10+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"Pharma stock engaged in the business of manufacturing, sale, and research and development of generic pharmaceutical products, APIs\u2019 and many others jumped 8 percent in the day\u2019s trade upon filing its first Drug Master File of recombinant Human Albumin 20 percent with the USFDA.\u00a0","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-8-after-company-filed-its-first-drug-to-treat-blood-volume-loss-with-usfda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock jumps 8% after company filed its first drug to treat blood volume loss with USFDA\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/125769","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=125769"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/125769\/revisions"}],"predecessor-version":[{"id":125771,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/125769\/revisions\/125771"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/125304"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=125769"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=125769"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=125769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}